Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Gross Margin (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 2 years of Gross Margin data on record, last reported at 58.45% in Q3 2025.

  • For Q3 2025, Gross Margin rose 1355.0% year-over-year to 58.45%; the TTM value through Sep 2025 reached 34.31%, changed N/A, while the annual FY2024 figure was 23.07%, 1589.0% down from the prior year.
  • Gross Margin reached 58.45% in Q3 2025 per TNXP's latest filing, up from 63.76% in the prior quarter.
  • Across five years, Gross Margin topped out at 61.18% in Q1 2025 and bottomed at 63.76% in Q2 2025.